Publications by authors named "Daniel Burge"

Claim this Profile
E
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Daniel J Burge, Victoria P Werth, Susan A Boackle, James Posada

Lupus Sci Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
James Posada, Saba Valadkhan, Daniel Burge, Kristen Davies, Jessica Tarn

Arthritis Rheumatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Daniel Burge

J Am Acad Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Daniel Burge

J Am Acad Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.
John R Doedens, Wendell D Jones, Kay Hill, Michael J Mason, Vivian H Gersuk, Daniel J Burge

J Immunol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Daniel J Burge, Stephen A Bookbinder, Alan J Kivitz, Roy M Fleischmann, Cathye Shu

Clin Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.
Phillip J Mease, Christopher T Ritchlin, Richard W Martin, Alice B Gottlieb, Scott W Baumgartner, Daniel J Burge

J Rheumatol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Edward C Keystone, Michael H Schiff, Joel M Kremer, Shelly Kafka, Michael Lovy, Daniel J Burge

Arthritis Rheum· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etanercept and squamous cell carcinoma.
Daniel Burge

J Am Acad Dermatol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Joel M Kremer, Michael E Weinblatt, Arthur D Bankhurst, Ken J Bulpitt, Roy M Fleischmann, Daniel J Burge

Arthritis Rheum· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Daniel J Lovell, Edward H Giannini, Andreas Reiff, Olcay Y Jones, Rayfel Schneider, Daniel J Burge

Arthritis Rheum· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis